Scientists at the University of Illinois at Chicago have developed a way to identify the beginning of every gene — known as a translation start site or a start codon — in bacterial cell DNA with a single experiment and, through this method, they have shown that an individual gene is capable of coding for more than one protein.
Shield Diagnostics, an Andreessen Horowitz-backed clinical laboratory tackling antibiotic resistance by bringing precision medicine to infectious disease, announced the launch of Target-NG, a rapid molecular test for antibiotic susceptibility in Neisseria gonorrhoeae.
Advanced Biological Laboratories (ABL), S.A., a Luxembourg-based diagnostics company and leader in virology genotyping, and Mayo Clinic Laboratories have announced a collaboration. The two organizations are working together to develop a clinical test that will detect mutations associated with antiviral resistance in human cytomegalovirus.
UNC School of Medicine scientists uncovered a possible reason why some breast cancers are so aggressive and difficult to treat: an enzyme called USP21 promotes proliferation of basal-like breast cancer and is upregulated in a significant percentage of patient tumors. It could become a drug target.
An international panel of the foremost researchers on infectious disease and antimicrobials has formed new guidelines on the use of polymyxins, a class of antibiotics employed as a last resort to treat deadly, drug-resistant bacteria.
Tufts University and Tufts Medical Center unite decades of experience and expertise in infectious disease research and clinical care with the Tufts Center for Integrated Management of Antimicrobial Resistance to more effectively address the rise and spread of multi-drug resistant organisms.
Antibiotics survival mechanism: UC San Diego researchers have discovered an unexpected mechanism that allows bacteria to defend themselves against antibiotics, a surprise finding that could lead to retooled drugs to treat infectious diseases.
Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleosis.
The products of wastewater treatment have been found to contain trace amounts of antibiotic resistant DNA. These products are often reintroduced to the environment and water supply, potentially resulting in the spread of antibiotic resistance.
U.S. Food and Drug Administration Approves New Drug that Could Bring Relief to Millions of People with Treatment-Resistant Depression
Each year, approximately 5 million patients in the United States receive treatment that includes the insertion of a medical device such as a catheter, which puts them at increased risk of potentially life-threatening infection. Researchers have found a strategy that greatly reduced both overall infection and infection with antibiotic-resistant bacteria in a group of these patients. The results of their study were published today in the online issue of The Lancet.
Neutrons used to study how an antibacterial peptide fights bacteria; decade-long study finds higher CO2 levels caused 30 percent more wood growth in U.S. trees; ultrasonic additive manufacturing to embed fiber optic sensors in heat- and radiation-resistant materials could yield safer reactors; ORNL analyzes “dark spots” where informal neighborhoods may lack power access; new Transportation Energy Data Book released.
Researchers at Indiana University have invented a new method to observe bacterial build cell walls in real time that could contribute to the search for new antibacterial drugs.
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified how prostate cancer transforms into a deadly treatment-resistant subtype following treatment with anti-androgen therapy. Their findings—which include the metabolic rewiring and the epigenetic alteration that drives this switch— reveal that an FDA-approved drug holds potential as a NEPC treatment. The research also uncovers new therapeutic avenues that could prevent this transformation from occurring. The study was published in Cancer Cell.
Grocery store aisles are stocked with products that promise to kill bacteria. However, new research from Washington University in St. Louis finds that a chemical that is supposed to kill bacteria is actually making them stronger and more capable of surviving antibiotic treatment.
Over-testing for urinary tract infections (UTIs) leads to unnecessary antibiotic use, which spreads antibiotic resistance. Infectious disease specialists at Washington University School of Medicine in St. Louis made changes to hospital procedures that cut urine tests by nearly half without compromising doctors’ abilities to detect UTIs.
With a $3.34M grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health Case Western Reserve University School of Medicine is conducting research that could help physicians better understand how bacteria such as B. multivorans resist antibiotics, potentially leading to improved treatments.
Physicists at McMaster University have for the first time identified a simple mechanism used by potentially deadly bacteria to fend off antibiotics, a discovery which is providing new insights into how germs adapt and behave at a level of detail never seen before.
A high proportion of multidrug-resistant tuberculosis (TB) cases can be cured in conflict-affected communities with molecular diagnostics, shorter treatment periods and socioeconomic incentives, according to the results of a large, long-term study in the Democratic Republic of Congo.
Even as hospitals try to cut back on prescribing powerful but risky antibiotics called fluoroquinolones, a new study shows that many patients still head home with prescriptions for the drugs -- increasing their risk of everything from "superbug" infections to torn tendons. In fact, the hospitals that are actively trying to reduce inpatient fluoroquinolone use were twice as likely to discharge patients with a new prescription for one of them.
A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.
We rely on antibiotics to treat bacterial infections, but the rise of antibiotic-resistant bacteria forces doctors and patients to contend with shifting treatment plans. Furthermore, current laboratory tests to determine what bacteria is causing a particular infection takes days to complete and can be too late for the patient. Mechanical engineers in Korea recently developed a microchip antibiotic testing platform that takes only six to seven hours to determine the appropriate medication.
A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
. In an exhaustive search of microbes from more than 1,400 insects collected from diverse environments across North and South America, a UW-Madison research team found that insect-borne microbes often outperformed soil bacteria in stopping some of the most common and dangerous antibiotic-resistant pathogens.
A scientific team from Case Western Reserve University School of Medicine and Cleveland Clinic has developed a new way to identify second-line antibiotics that may be effective in killing germs already resistant to a first-line antibiotic – potentially helping overcome antibiotic resistance. This new research provides an approach clinicians could consult when deciding which antibiotic treatment courses will be most effective for patients.
The 3D structure of McbBCD, an enzyme (protein) that makes the potent antibiotic microcin B17 from a smaller protein known as a peptide, as revealed by X-ray crystallography. The red spheres show chemical "cycles" formed by the enzyme that are required for antibacterial activity. Image: Dmitry Ghilarov High Res MEDIA CONTACT Todd Bates 848-932-0550 [email protected] YOU MAY ALSO LIKE Scientists Use Bear Saliva to Rapidly Test for Antibiotics Scientists at Rutgers and universities in Russia, Poland and England have solved a nearly 30-year mystery – how the molecular machinery works in an enzyme that makes a potent antibiotic. The findings, which appear in the journal Molecular Cell, provide the tools to design new antibiotics, anticancer drugs and other therapeutics.
While more than 32 million individuals in the U.S. have a documented penicillin allergy in their medical record, studies have shown that more 95 percent actually can be treated safely with this class of antibiotics, improving treatment outcomes and reducing the risk of infection with dangerous resistant pathogens such as Clostridium difficile (C. difficile). A review article in the January 15 issue of JAMA recommends best practices for evaluation of reported penicillin allergies and provides clinicians with guidance and tools to help determine appropriate procedures based on the severity of previously reported reactions.
In studying a bacterium that causes disease in hospitalized people, researchers at Washington University School of Medicine in St. Louis have figured out a key step in the transmission of antibiotic resistance from one bacterium to another. Their insight suggests a new strategy for stopping the spread of antibiotic resistance.
Research using small genome bacterial to study how changes in the genome allow persister cells to gain resistance to antibiotics also helped an undergraduate find her career path.
Sanjay Gupta, PhD, of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center will receive $962,000 over three years to investigate drug resistance mechanisms in prostate cancer. The funding is part of the Department of Defense’s Idea Award program, that aims to improve quality of life by decreasing the impact of cancer on active duty service members and their communities. Gupta will use the award and clinically-approved drugs to develop a safe, efficacious, and cost-effective combination therapy for castrate-resistant prostate cancer.
The increasing prevalence of antibiotic resistance in the U.S. appears more closely linked with their occasional use by many people than by their repeated use among smaller numbers of people, according to a large new study from Harvard T.H. Chan School of Public Health.
Researcher shows the two most common means of resistance to BRAF and MEK inhibitors are actually connected processes and can be targeted by other therapies.
Researchers in Oregon State University's College of Engineering have performed a first-of-its-kind genotype and phenotype study of the prevalence of multiple-antibiotic-resistant enteric bacteria in septic systems and soils in Vietnam.
Assistant Professor Iram Surtaj will use a new imaging technique to identify drugs that can disrupt overexpression of multidrug resistance protein 1, one of the main mechanisms through which cancer cells gain resistance to chemotherapy drugs.
David Cheresh, Distinguished Professor at University of California San Diego School of Medicine, received $4.2 million National Cancer Institute Outstanding Investigator Award to continue his research into cancer’s ability to overcome stress, gain drug resistance and metastasize.
A team of University of California San Diego School of Medicine researchers have been awarded a $1 million Stand Up To Cancer grant to test drugs that block signals that play a critical role in driving growth and progression of pancreatic cancer.
Trying to understand why some breeds of sheep are more susceptible to parasitic infection than others is a puzzle, but researchers in the WVU Davis College of Agriculture, Natural Resources and Design are putting it together piece by piece.
Antibiotic resistance is predicted to be the No. 1 cause of death in the world by 2050, but a team of scientists and physicians at The University of Texas Health Science Center at Houston (UTHealth) is determined to help stop this grave prediction from becoming a reality.
Gerry Wright, Director of the Michael G. DeGroote Institute for Infectious Disease Research, talking about the concern of antibiotic resistance (with infographic).
Researchers have trained a machine learning algorithm to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis—the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria. The approach could be used to predict resistance in other infection-causing pathogens.
Multiple myeloma doesn’t play around. Within five years of being diagnosed with this form of blood cancer, about half of all patients die from it. And even if they initially respond well to treatment, the cancer can hide in their bone marrow for years before reemerging in a tougher-to-treat form.
Steffanie Strathdee, PhD, associate dean of global health sciences at University of California San Diego School of Medicine, was named today one of TIME magazine’s 50 Most Influential People in Health Care for 2018, which identifies people who “have changed the state of health care in America this year, and bear watching for what they do next.”
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria. Every treated mouse survived. The breakthrough study, published in Scientific Reports, suggests infections in humans might be cured the same way.
Antibiotic resistance is an urgent problem globally when treating many infections. Now a team of scientists believe a better understanding of the mechanisms of pili, the hair-like surface appendages on bacteria that initiate infection, could hold a key to developing new and more effective therapeutics.
A low-cost, easy-to-replicate test for tuberculosis might help developing nations better identify and treat the infectious and sometimes deadly disease, new research suggests.
CU Boulder researchers have identified a family of small molecules that turn off defense mechanisms inside bacteria that enable them to resist antibiotics. The compounds could ultimately be given alongside existing medications to rejuvenate them.
Using a clinical checklist to identify eligible patients, doctors were able to shorten the antibiotic duration for patients with uncomplicated staphylococcal bloodstream infections by nearly two days, Duke Health researchers report.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
A new study suggests that defenses against extreme temperatures give E. coli bacteria an advantage in fending off certain drugs. The work could help doctors administer antibiotics in a more precise way.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right